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Development of a characterised 
tool kit for the interrogation of 
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responses
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Michael J. Haley  1, Eric Karran4, Hugh Nuthall5, Peter J. Atkinson6, Lee A. Dawson7, Carol 
Routledge8, Stuart M. Allan1, Sally Freeman3, Janet Brownlees2 & David Brough  1
Inflammation is an established contributor to disease and the NLRP3 inflammasome is emerging as a 
potential therapeutic target. A number of small molecule inhibitors of the NLRP3 pathway have been 
described. Here we analysed the most promising of these inhibitor classes side by side to assess relative 
potency and selectivity for their respective putative targets. Assessed using ASC inflammasome-speck 
formation, and release of IL-1β, in both human monocyte/macrophage THP1 cells and in primary 
mouse microglia, we compared the relative potency and selectivity of P2X7 inhibitors, inflammasome 
inhibitors (diarylsulfonylurea vs. the NBC series), and caspase-1 inhibitors. In doing so we are now able 
to provide a well characterised small molecule tool kit for interrogating and validating inflammasome-
dependent responses with a range of nanomolar potency inhibitors against established points in the 
inflammasome pathway.
Inflammation is a protective host response to infection, but when it occurs during non-communicable dis-
ease it is often damaging and contributes to an acceleration of pathology and a worse outcome. An important 
inflammatory process in disease is the activation of a multi-molecular complex called the NLRP3 inflammasome 
(Fig. 1)1. The NLRP3 inflammasome consists of a pattern recognition receptor (PRR), which in this case is NLRP3 
(NOD-like receptor (NLR) family, pyrin domain–containing protein 3 (NLRP3)), an adaptor protein called ASC 
(apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (CARD)), 
and pro-caspase-12. Described mainly in cells of haematopoietic lineage NLRP3 requires priming by pathogen 
associated molecular patterns (PAMPs) and subsequently becomes activated by a further PAMP, or by damage 
associated molecular patterns (DAMPs) causing a disruption to cellular homeostasis1. A commonly described 
DAMP activating NLRP3 is high levels of extracellular ATP which is sensed by the cell surface P2X7 receptor3. 
Activation of P2X7 induces efflux of K+ causing the association of the protein NEK7 (never in mitosis A-related 
kinase 7) to NLRP3 facilitating its activation4. Active NLRP3 then nucleates the oligomerisation of ASC molecules 
into inflammasome ‘specks’ which provide the platform for the proximity-induced auto-activation of caspase-15. 
Caspase-1 then cleaves the cytokine precursor molecules pro-IL-1β and pro-IL-18 to active molecules which are 
then secreted through an unconventional secretory route involving gasdermin D pores to the extracellular space 
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where they drive inflammation6–8. Once formed the ASC specks can also be released and are stable in the extra-
cellular environment where they further propagate inflammatory processes9,10.
The NLRP3 inflammasome and IL-1β are implicated in diverse and major diseases including Alzheimer’s 
disease11,12, diabetes13, cardiovascular disease14, and many others. The importance of IL-1β to disease was high-
lighted following the recent publication of the CANTOS trial, where patients with a history of myocardial infarc-
tion were treated with canakinumab, a monoclonal antibody targeting IL-1β15. In the CANTOS trial it was found 
that canakinumab treatment reduced the rate of recurrent cardiovascular events, and cancer mortality, in addition 
to many other clinical outcomes15. However, biologicals such as canakinumab may not be suitable for the treat-
ment of diseases where penetrance across the blood brain barrier is important, and so a small molecule inhibitor 
of NLRP3/IL-1 is desirable.
A number of small molecule inhibitors for the P2X7-NLRP3-Caspase-1 axis have been described16. The aim of 
this research was to take a selection of what we considered to be the most promising lead compounds from the lit-
erature. We focussed our study on known and potent molecules for defined points in the pathway which included 
antagonists of the P2X7 receptor (CE-224,53517, AZD905618, and two 5,6-dihydro-[1,2,4]triazolo[4,3-a]-pyrazine 
P2X7 antagonists (compounds 25 and 26 from19), the diarylsulfonylurea series (glyburide through to the cytokine 
release inhibiting drugs (CRIDs), including MCC95020–22), the caspase-1 inhibitor belnacasan (VX-765)23, and 
compare these to several analogues of the recently described Novel Boron Compound (NBC) inflammasome 
inhibitor series of boron-containing inhibitors24 (Fig. 1). This selection of molecules is by no means comprehen-
sive and it is important to acknowledge the recent development of additional NLRP3 inhibitors not tested here 
such as CY-0925, and OLT117726. All molecules were tested in pre- and post-differentiated human macrophage 
THP1 cells using ASC speck formation and IL-1β release as endpoints, and in primary cultures of mouse micro-
glia using IL-1β release as an endpoint. Thus we are now able to provide quantitative and comparable data for 
some of the most potent P2X7-NLRP3-caspase-1 inhibitors available.
Results
The structures of the molecules tested in the assays reported below are shown in Table 1. Human THP1 cells 
stably expressing ASC-Cerulean9 were either left undifferentiated or differentiated with phorbol 12-myristate 
13-acetate (PMA, 0.5 µM, 3 h) before priming with bacterial endotoxin (LPS, 1 µg/ml overnight). Cells were then 
treated with the pan-caspase inhibitor ZVAD (50 µM, 30 min) to prevent pyroptosis and 10 point concentration 
response curves for each inhibitor were generated in triplicate measuring ASC speck formation in response to the 
K+ ionophore nigericin (10 µM, 1 h) using the IN Cell Analyzer 2000 imaging system (Fig. 2, and see methods). 
Under the current experimental conditions the THP1 cells failed to respond to ATP (up to 10 mM), so P2X7 
Figure 1. Inflammasome pathway and inhibitors. The action of LPS on TLR4 induces the translocation of 
NFκB to the nucleus and triggers the transcription of pro-IL-1β and NLRP3. A second signal (e.g. ATP acting at 
P2X7), causes NLRP3, ASC and pro-caspase-1 to oligomerize and form an inflammasome speck, which permits 
the recruitment and activation of caspase-1 and the subsequent cleavage of pro-IL-1β into its active form which 
is then released. The inhibitors were added directly before the second signal, and were characterised as P2X7 
receptor inhibitors, a caspase-1 inhibitor, or the NLRP3 inhibiting diarylsulfonylurea and NBC series inhibitors. 
The outline of the cell is courtesy of Servier Medical Art.
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Drug Structure Reference
P2X7 antagonists
CE-224,535 17
AZD9056 18
25 (from [1] 19
26 (from [1] 19
Diarylsulfonylurea inflammasome inhibitor series
Glyburide 20
CP-412,245 20
CP-424,174 20
CRID1 21
Continued
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Drug Structure Reference
CRID2 21
MCC950 21,22
NBC inflammasome inhibitor series
BC7 38
BC23 39
NBC6 24
NBC11 24
NBC12 24
NBC13 24
Continued
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inhibition was not evaluated in these cells. The results of the screen can be seen in Table 2. From the diarylsulfo-
nylurea inflammasome inhibitor series (including glyburide, CP-412,245, CP-424,17420, CRID1, CRID221, and 
MCC95022), the most potent inhibitor of ASC speck formation was MCC950 with an IC50 of 3 nM in undiffer-
entiated THP1 cells (Table 2). From the NBC inflammasome inhibitor series24 the best inhibitor was NBC19 
with an IC50 of 60 nM based on speck formation in differentiated THP1 cells (Table 2). The caspase-1 inhibitor 
VX-765 had no effect, as expected, as the formation of the ASC speck does not require caspase-1 (Table 2). The 
above experiment was repeated in differentiated THP1 cells except without ZVAD and with IL-1β release as the 
endpoint (Table 3). Under these conditions the best inhibitor from the diarylsulfonylureas was still MCC950 with 
an IC50 of 4 nM (Table 3). NBC19 was still the best of the NBC series with an IC50 of 80 nM for inhibiting nigericin 
induced IL-1β release, and in this assay VX-765 inhibited IL-1β release with an IC50 of 10 nM (Table 3).
We next tested the molecules in cells relevant to CNS disease. Cultured mouse neonatal microglia were pre-
pared as described previously27 where inflammasome responses are known to be microglia dependent27,28. Cells 
were primed with LPS (1 μg/ml, 3 h), then incubated with the inhibitors using a 10-point concentration response 
curve, before incubation with either nigericin (10 μM, 1 h), or ATP (5 mM, 1 h), in a minimum of four separate 
experiments. IL-1β release was measured as the endpoint. The best inhibitor from the diarylsulfonylurea series 
was again MCC950 with an IC50 of 60 nM against ATP-induced IL-1β release (Table 3). The P2X7 antagonists had 
no effect against nigericin-induced IL-1β release but were effective against ATP with AZD9056 and compound 
26 (from19) both inhibiting ATP-induced IL-1β release with an IC50 of 30 nM (Table 3). NBC19 was again the 
most effective of the NBC series with an IC50 of 850 nM against ATP-induced IL-1β release (Table 3). VX-765, 
the caspase-1 inhibitor, inhibited ATP-induced IL-1β release with an IC50 of 50 nM (Table 3). There is debate in 
the literature as to whether responses are conserved between cultured neonatal microglia and adult microglia29,30. 
Thus we isolated primary adult mouse microglia as previously described31, and treated them as above (e.g. LPS, 
1 μg/ml, 3 h followed by 15 min of inhibitor, followed by 5 mM ATP for 1 h). At this stage we selected the 4 best 
compounds across the respective classes (i.e. the P2X7 inhibitor compound 26 from19, MCC950, NBC19, and 
VX-765; dose responses to ATP and nigericin shown in Fig. 3a and b respectively). ATP-induced NLRP3 inflam-
masome activation and IL-1β secretion was conserved in isolated adult microglia and the 4 inhibitors (all tested 
at 10 μM, n = 10) effectively inhibited IL-1β release (Fig. 3c).
Discussion
Given the established role for IL-1 in human disease32, and preclinical evidence showing the involvement of 
NLRP3 in many major diseases including Alzheimer’s disease11,12,33, diabetes34, and cardiovascular disease14, the 
NLRP3 inflammasome is emerging as a potential drug target. Here we have characterised and compared a num-
ber of compounds known to be inhibitory across the various points in the NLRP3 pathway (Fig. 1). By testing 
the compounds side by side in validated assays we have been able to show that there are potent inhibitors for a 
number of steps of the NLRP3 pathway. The P2X7 inhibitor compound 26 is of interest for use in CNS models of 
disease as it is known to have high permeability across the blood brain barrier19, and we show here that it is very 
effective at inhibiting inflammasome activation and IL-1β release against ATP (Tables 2 and 3). Compound 26 
did not inhibit nigericin induced NLRP3-dependent IL-1β release (Tables 2 and 3) confirming it as a potent and 
selective inhibitor of the P2X7-NLRP3 axis. As reported previously, MCC950 is a potent and selective inhibitor 
of NLRP3 inflammasomes in vitro and in vivo22 (Tables 2 and 3). Caspase-1 activation is an outcome of inflam-
masome activation and so we predicted the caspase-1 inhibitor VX-765 would be effective at inhibiting IL-1β 
Drug Structure Reference
NBC19 24
Caspase-1 inhibitor
VX-765 23
Table 1. Inhibitor series characterised and compared in this study. Drugs targeting different points of the 
NLRP3 pathway assessed in this study. Shown is the name, structure, and original reference for the compounds 
tested. Compounds tested belong to one of 4 inhibitor classes: P2X7 receptor inhibitors, diarylsulphonylurea 
inhibitors, NBC series inhibitors, and a caspase-1 inhibitor.
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release but not ASC speck formation which was confirmed (Tables 2 and 3). That VX-765 did not inhibit ASC 
speck formation confirmed that it was targeting caspase-1 specifically downstream of inflammasome activation 
(Table 2, Fig. 2). The comparison between the diarylsulfonylurea series20–22, and our NBC series24, showed that the 
best diarylsulfonylureas were in general more potent, and the most potent of them, MCC950, was the most active 
compound tested (Tables 2 and 3). Our recent work described NBC6 (with an IC50 of 570 nM) as an effective 
inhibitor of the NLRP3 inflammasome in vitro and in vivo24. We report here that NBC19 has improved activity, 
with a significantly improved IC50 of 60 nM in the ASC inflammasome speck assay in differentiated THP1 cells 
(Table 2). Thus we have characterised a ‘tool kit’ for dissecting inflammasome dependent responses identifying 
potent and well characterised reagents.
Here we established 2 protocols for assaying the effects of the inhibitors. The assay developed using the 
THP1-Cerulean cells9, was particularly sensitive, consistently yielding lower IC50 values than the primary glial 
cultures (Tables 2 and 3). Given that the IC50 established from the differentiated THP1 cells for IL-1β release more 
or less mirrored the IC50 obtained in the ASC speck assay, we think that the difference between the THP1 cells and 
the glia likely reflects the inherent variability between primary cultures when compared to using a pure clonal cell 
population. We also established that inflammasome responses are robust and comparable in acutely isolated pri-
mary microglia from the adult brain (Fig. 3c), giving confidence to the data generated using neonatal microglia.
Figure 2. Compounds targeting NLRP3 but not downstream caspase-1 inhibit nigericin-induced formation 
of ASC specks in THP1-ASC-Cerulean macrophages. THP1-ASC-Cerulean macrophages were seeded in 96 
well plate format, differentiated with PMA (0.5 µM, 3 h), pre-treated with compound for 30 min (VX-765 (a), 
MCC950 (b) and NBC19 (c)) before being stimulated with nigericin (10 µM, 1 h), fixed and imaged on GE 
InCell2000. Specks can this way be visualized and counted. Compounds targeting the NLRP3 inflammasome 
assembly induced a dose-dependent reduction in the number of specks. Dose response curves (d) showing 
the number of formed specks and the cell death for each compound. Scale bar depicts 20 µm. Respective 
concentration of compound and DMSO controls are indicated in the images. Data represent 3 separate cultures.
www.nature.com/scientificreports/
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It is important to note, that while our research has focussed on targeting the NLRP3 inflammasome in innate 
immune cells, NLRP3 is also important in non-immune cell function. For example, the NLRP3 inflammasome 
is present in epithelial cells in many tissues and is known to be involved in many physiological processes35. There 
is evidence that epithelial cell NLRP3 also regulates caspase-1-dependent release of pro-inflammatory cytokines 
such as IL-1β (e.g.36), but it is also reported to have other functions such as regulating the activation of sterol reg-
ulatory element binding proteins (SREBPs) which repair the plasma membrane of epithelial cells in response to 
pore forming bacterial toxins37. Thus the ‘toolkit’ described here will also be of value to scientists studying NLRP3 
function in non-immune cells such as epithelial cells.
In summary, the data provided here give comparable quantitative data on inhibitors of the NLRP3 inflam-
masome pathway and identify their selectivity across the particular points of intervention, identifying them as a 
valuable tool kit for interrogating inflammasome dependent responses in cell based models.
Materials and Methods
Inhibitors. The NBC molecules were synthesised and prepared at the University of Manchester as described 
previously24. MCC950 (Sigma-Aldrich, Dorset, UK) and VX-765 (Selleckchem, Munich, Germany) were pur-
chased. All other compounds in the P2X7 and diarylsulfonylurea series were synthesised following the relevant 
published literature either in house at LifeArc or at GVK Biosciences, Bengaluru, India.
THP1 culture and differentiation. ASC-Cerulean expressing THP1 cells were grown in RPMI, 10% FBS 
and 1% Pen/Strep. Cells were differentiated using 0.5 µM PMA for 3 h and used for assays the next day.
NLRP3 inflammasome activation in THP1 cells. ASC-Cerulean expressing THP1 cells were 
pre-incubated with compound (1% final DMSO) for 30 min before being stimulated with 10 µM nigericin for 
1 h. Pre-differentiated cells were treated with the pan caspase inhibitor Z-VAD-FMK (Promega, Southampton, 
UK; 50 µM, 30 min) during compound incubation. Supernatants were collected for quantification of IL-1β using 
mesoscale Tissue Culture Kit (K151AGB) and cells were fixed for the speck assay.
Speck assay and analysis. ASC-Cerulean expressing THP1 cells were fixed with 4% formaldehyde for 
15 min at room temperature, washed with PBS and stained with HCS Red (Invitrogen, Loughborough, UK) to 
visualize nuclei. Images were acquired on the GE IN Cell 2000 and analysed in Workstation to count both nuclei 
and cerulean-labelled ASC specks.
Preparation of neonatal glial cultures. Mice (C57BL/6 strain) were maintained under standard labora-
tory conditions (20 ± 2 °C, 12-h light cycle, humidity of 40–50%, 12 h light cycle, ad libitum access to water and 
standard rodent chow). All procedures were performed by appropriate personal and under project licences, in 
accordance with the Home Office (Animals) Scientific Procedures Act (1986) and approved by the Home Office 
and the local Animal Ethical Review Group, University of Manchester. Each litter was considered as an n number, 
and a minimum of 3 litters was used to test each compound.
Drug
ASC speck formation in  
pre-differentiated THP1 cells
ASC speck formation in  
post-differentiated THP1 cells
Diarylsulfonylurea inflammasome inhibitor series pIC50 IC50 (μM) pIC50 IC50 (μM)
Glyburide 5.4 4.22 6.1 0.89
CP-412,245 7.6 0.03 6.9 0.12
CP-424,174 7.7 0.02 7.5 0.03
CRID1 7.6 0.02 7.6 0.02
CRID2 8.1 0.01 8.4 0.004
MCC950 8.6 0.003 8.3 0.005
NBC inflammasome inhibitor series
BC7 5.5 2.82 5.5 3.04
BC23 5.2 6.35 4.8 14.4
NBC6 5.2 6.31 5.3 5.06
NBC11 6.1 0.83 5.8 1.69
NBC12 5.9 1.3 6.2 0.6
NBC13 5.9 1.13 6.8 0.15
NBC19 5.6 2.41 7.2 0.06
Caspase-1 inhibitor
VX-765 — — — —
Table 2. Inhibition of nigericin-induced ASC speck formation in pre- and post-differentiated THP1 cells. Cells 
were primed with 1 µg/ml LPS overnight, treated with inhibitors for 30 minutes and further stimulated with 
nigericin (10 µM, 1 h). In pre-differentiated cells caspases were inhibited by Z-VAD-FMK (Supernatants of 
post-differentiated cells were harvested for MSD quantification of IL-1β (Table 3)). pIC50 and IC50 values were 
determined by vehicle-normalised quantification of cells showing ASC specks, and obtained from at least 3 
independent experiments.
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Brains were harvested from 3–4 days old mice under aseptic conditions, and olfactory bulbs, cerebellum, 
and meningeal layers, were gently removed. Brain tissue was mechanically digested, centrifuged, and cells resus-
pended in media and seeded on cell culture flasks. Cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Sigma-Aldrich), 10% fetal bovine serum (FBS, Life Technologies, Warrington, UK), 100 U/ml peni-
cillin and 100 μg/ml streptomycin (Sigma-Aldrich). Media was changed every 4–5 days until cells reached 80% 
confluence (around day 10–13 in vitro (div)). Cells were then trypsinized (0.5% Trypsin EDTA, 2 min at 37 °C, 
Sigma-Aldrich) and gently scraped, counted and seeded on plates (1.7 × 105 cells/ml). After 2–3 days, cells were 
ready for further experiments.
Preparation of adult microglia. Adult C57BL/6 mice were perfused with ice-cold Hank’s Balanced 
Salts Solution (HBSS) and brains kept in cold HBSS. After removal of cerebellum and meningeal layers, brains 
were diced, and enzymatically processed using as per manufacturer’s instructions using a MACS Neural Tissue 
Dissociation Kit (P) (Miltenyi Biotech, Bisley, UK). Brains were then mechanically homogenised using a Dounce 
homogeniser, and myelin removed from the resulting cell suspension using a one-step 30% Percoll gradient31. 
Microglia were then isolated using magnetic CD11b + beads (Milteny Biotech), and seeded on poly-L-lysine 
coated plates (~1.7 × 105 cells/ml), and maintained with DMEM (with 10% fetal bovine serum and 1% penicillin 
streptomycin) supplemented with 10 ng/ml of recombinant mouse M-CSF (R&D systems, Abingdon UK), and 
50 ng/ml of recombinant human TGF-β. Media was changed at 3 days, and cells treated after 7 days in culture.
Inflammasome activation assays in glia. Fresh media (DMEM, 10% FBS, 100 U/ml penicillin and 
100 μg/ml streptomycin) was added before starting the treatments. Cells were treated with gel filtration chro-
matography purified LPS (1 µg/ml, 3 h, E.coli O26:B6, L2654, Sigma-Aldrich) and then the media was changed 
to serum free media before the addition of drugs that were dissolved in DMSO (except MCC950, in PBS), and 
were added as a 10 point dose response from 0.01–100 µM (compounds shown in Table 1). After 15 min incuba-
tion with the drugs (or vehicle), the NLRP3 inflammasome was activated as follows by adding ATP (5 mM) or 
nigericin (10 µM) for 1 h. Supernatants were collected and used for further analysis of cell death and IL-1β release.
Lactate dehydrogenase measurement of cell death. Lactate dehydrogenase (LDH) release was used 
as a measure of cell death using a CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega). Following manu-
facturer’s instructions, absorbance at 490 nm was measured and converted into cell death values.
Drug
Nigericin-induced IL-1β release 
from post-differentiated THP1 cells
Nigericin-induced IL-1β release 
from neonatal microglia
ATP-induced IL-1β release 
from neonatal microglia
P2X7 antagonists pIC50 IC50 (µM) pIC50 IC50 (μM) pIC50 IC50 (μM)
CE-224,535 — — — — 6.18 0.66
AZD9056 — — — — 7.52 0.03
25 (from19) — — — — 7 0.1
26 (from19) — — — — 7.52 0.03
Diarylsulfonylurea inflammasome inhibitor series
Glyburide 6 1.12 4.68 20.81 4.57 26.86
CP-412,245 7.3 0.06 6.51 0.31 6.85 0.14
CP-424,174 7.9 0.01 6.51 0.31 6.92 0.12
CRID1 7.6 0.03 6.72 0.19 6.8 0.16
CRID2 8 0.01 6.74 0.18 6.66 0.22
MCC950 8.5 0.004 7 0.1 7.22 0.06
NBC inflammasome inhibitor series
NBC6 5.2 6.3 5.96 1.17 5.33 4.67
NBC11 5.8 1.66 5.84 1.44 5.53 2.93
NBC12 6.3 0.48 6 0.99 5.53 2.98
NBC13 6.4 0.41 6.06 0.87 5.69 2.02
NBC19 7.1 0.08 5.93 1.18 6.07 0.85
Caspase-1 inhibitor
VX-765 7.8 0.01 7.15 0.07 7.3 0.05
Table 3. Inhibition of nigericin and ATP-induced IL-1β release from post-differentiated THP1 cells and 
primary cultured neonatal microglia. THP1 cells were primed with 1 µg/ml LPS overnight, treated with 
inhibitors for 30 minutes and further stimulated with nigericin (10 µM, 1 h). ASC specks were analysed (Table 2) 
and supernatants used for MSD quantification of IL-1β release. pIC50 and IC50 values were determined by 
normalisation to vehicle-treated controls, and obtained from at least 3 independent experiments. Assays were 
performed using microglial cultures primed with LPS (1 μg/ml, 3 h), treated 15 minutes with the inhibitors, 
and further activated with ATP (5 mM, 1 h) or nigericin (10 μM, 1 h). pIC50 and IC50 values were determined by 
vehicle-normalised ELISA quantification of IL-1β, and obtained from at least 3 independent cultures (litters).
www.nature.com/scientificreports/
9SCiENtiFiC REPORtS |  (2018) 8:5667  | DOI:10.1038/s41598-018-24029-3
Figure 3. Inhibition of IL-1β secretion in neonatal and adult microglia. 50 × 104 cells were treated with LPS 
(1 μg/ml, 3 h), then with the selected inhibitors (VX-765, P2X7R inhibitor (compound 26 from reference19), 
NBC19 and MCC950, 10 μM for 15 min), and then activated with ATP (a, 5 mM, 1 h) or nigericin (b, 10 μM, 
1 h). Graphs are presented showing cell death curves (in grey) and the inhibition of IL-1β release (in black) 
from neonatal cultures of microglia (a and b). The four inhibitors tested significantly reduced the secretion of 
IL-1β both in neonatal microglia and adult microglia (c). Statistical significance (vs. LPS + ATP): *p < 0.05; 
**p < 0.01; nd: not-detectable. Scale bar = 200 µm.
www.nature.com/scientificreports/
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IL-1β measurements. THP1 cells. Secretion of IL-1β was quantified using mesoscale Tissue Culture Kit 
(K151AGB) following the manufacturer’s instruction.
Microglial cells. Secretion of IL-1β was quantified by ELISA using DuoSet® kits (R&D Systems) following the 
manufacturer’s instructions.
Statistical analysis. THP1 cells. For both readouts, speck assay and IL-1β quantification, half maximal 
inhibitory concentration (IC50) of drugs was determined by fitting the data to a four parameter logistic equation 
(Nonlinear Regression, Sigmoidal, 4PL) in GraphPad Prism version 7.03. Mean and SEM values are plotted from 
at least 3 experiments.
Glia. For each assay IL-1β levels were calculated against a four-parameter logistic (4-PL) curve fit, using 
GraphPad Prism version 7.00 for Windows, GraphPad Software (USA). All values are expressed as a percentage 
of vehicle conditions or as mean ± standard error of the mean (SEM), and a minimum of 3 litters (n = 3) was used 
for each tested compound. The half-maximal inhibitory concentration (IC50, μM) for each drug was determined 
by fitting the data to a four-parameter logistic equation using GraphPad Prism. One way ANOVA was performed 
on IL-1β values for the adult and neonatal microglia experiments (comparing vs. LPS + stimulus). Holm-Sidak 
post hoc tests were performed if statistical significance (p value < 0.05) was achieved, and indicated in the graphs 
as follows: *p < 0.05; **p < 0.01; ***p < 0.001.
Data availability. The data that support the findings of this study are available from the corresponding 
author on request.
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